Rigel Pharmaceuticals, Inc..
RIGL.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing, and commercializing novel, targeted therapies that improve the lives of patients with hematologic disorders, cancer, and rare immune diseases. The company focuses on developing therapies that address unmet m...Show More
Better Health for All
20
Rigel Pharmaceuticals' core business is dedicated to developing novel therapies for serious conditions like hematologic disorders, cancer, and rare immune diseases
1
, with its primary product REZLIDHIA for AML demonstrating durable remissions
2
and a 35% complete remission rate.
3
The company has no reported revenue from products with negative health outcomes. Rigel provides detailed safety information, including boxed warnings for differentiation syndrome and hepatotoxicity, in its press releases, demonstrating comprehensive risk disclosures.
4
The company invests in research and development through a multi-year strategic alliance with MD Anderson
5
, and its clinical trials are designed to assess safety, tolerability, and efficacy.
6
Fair Money & Economic Opportunity
0
No evidence available to assess Rigel Pharmaceuticals, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
40
Rigel Pharmaceuticals reported a CEO-to-median employee pay ratio of 10:1 for fiscal year 2024.
1
As of December 31, 2024, none of the company's employees were represented by a collective bargaining arrangement.
2
The company had 162 full-time, 2 part-time, and 8 temporary employees and consultants as of December 31, 2024.
3
This means 8 out of 172 employees, or approximately 4.65%, are on temporary contracts. The company provides 100% of its employees with employer-funded health insurance, including access to innovative, flexible, and convenient health and wellness programs, and offers programs to support employees' physical and mental health.
4
Fair Trade & Ethical Sourcing
0
No specific, quantifiable evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. The articles primarily focus on internal company values, products, general corporate governance, and employee conduct, without detailing supply chain practices, certifications, audit frequencies, or incident reporting related to ethical sourcing. While Rigel mentions selecting Contract Manufacturing Organizations (CMOs) based on quality, environmental, and social considerations, and requiring certain vendors to follow business practices, these statements lack the specific quantitative data required to score any of the defined KPIs.
1
Honest & Fair Business
-20
Rigel Pharmaceuticals has an independent and anonymous reporting hotline (844-985-4115) and a web compliance portal.
1
The company has a policy of non-retaliation for employees reporting suspected violations, and the Chief Compliance Officer is responsible for investigating and tracking complaints.
2
The company has not had any financial restatements in the past five years, though a critical audit matter related to product sales allowances and discounts was noted.
3
The Board has affirmatively determined that all current directors, except for the Chief Executive Officer, are independent within the meaning of Nasdaq listing standards.
4
With 7 board members, this means 6 out of 7 (approximately 85.7%) are conflict-free.
5
Rigel has a Code of Conduct that prohibits all bribes and improper payments, requires compliance with the U.S. Foreign Corrupt Practices Act (FCPA), and includes policies on gifting and entertainment.
6
However, the policy lacks explicit details on training frequency or effectiveness metrics. The company obtains independent third-party verification (ethical committees’ approval) for conducting clinical research prior to human experimentation of its products.
7
It also mentions rigorous CMC practices, including contract oversight and quality control, and the selection of CMO partners based on quality standards, environmental, and social considerations.
8
Kind to Animals
0
Based on the provided information, there is insufficient evidence to determine Rigel Pharmaceuticals' alignment with the 'Kind to Animals' value. The company is involved in pharmaceutical research and development, which typically includes animal testing to ensure the safety and efficacy of new therapies.
1
However, the extent of this testing, the specific policies in place to minimize harm to animals, and any investments in alternative testing methods are not detailed in the provided article. Without this information, a neutral score is most appropriate. The materiality analysis indicates that animal testing is inherent in the pharmaceutical industry, but specific data on Rigel's practices is needed for a more accurate assessment.
No War, No Weapons
0
The provided articles, including the company's website, proxy statements, 10-K annual reports, and ESG report, do not contain any specific, concrete data points or explicit information regarding Rigel Pharmaceuticals' involvement in arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other activities related to the 'No War, No Weapons' ethical value. While Article 5 mentions 'Government contracts' revenue, it does not specify if these are defense-related, and given the company's biotechnology focus, such an inference cannot be made without explicit evidence.
1
Therefore, no KPIs can be scored based on the provided evidence.
Planet-Friendly Business
0
No evidence available to assess Rigel Pharmaceuticals, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific, concrete data points or facts regarding Rigel Pharmaceuticals' respect for cultures and communities were found in the provided articles.
1
The articles focus on general industry news, the company's business, therapies, career opportunities, and clinical trial pipeline, explicitly stating the absence of information relevant to community relations, cultural sensitivity, or social responsibility.
Safe & Smart Tech
0
No evidence available to assess Rigel Pharmaceuticals, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
The provided articles, including the SEC Form 10-K filing for the fiscal year ended December 31, 2023, and an ESG summary document, explicitly state that they do not contain specific quantitative data related to waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability scores, waste audit frequency, zero-waste certifications, waste disposal violations, material efficiency, packaging-to-product ratios, waste reduction targets, supplier waste requirements, or customer waste education.
1
The ESG document notes a commitment to environmental sustainability but lacks concrete data to support these claims.
2